John Stock to Spinal Fractures
This is a "connection" page, showing publications John Stock has written about Spinal Fractures.
Connection Strength
0.596
-
Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin. 2005 Dec; 21(12):1955-9.
Score: 0.247
-
Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. J Fam Pract. 2004 Oct; 53(10):789-96.
Score: 0.228
-
Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc. 2004 Sep; 52(9):1543-8.
Score: 0.057
-
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 Jan; 17(1):1-10.
Score: 0.047
-
Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008 Jan; 23(1):112-20.
Score: 0.018